Given the recent evidence that RAS-targeting ARBs and ACE-Is, associated with reduced incidence and delayed onset of cognitive decline in AD patients, are associated with reduced tau pathology and lower CSF tau level [14, 86, 87], as well as the ability of the ARB losartan to reverse Ang-II-mediated tau phosphorylation in aged rodents [8], further studies should address whether DIZE also modifies disease-related tau modifications in relation to cognitive decline. Here, AGT is linked to Alzheimer disease.